In Vivo CRISPR Gene Editing in Hereditary Angioedema

DM Cohn et al. N Engl J Med 2026;395:1471-1482. Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema

Background: “Lonvoguran ziclumeran (lonvo-z) — an investigational, in vivo gene-editing treatment based on clustered regularly interspaced short palindromic repeats (CRISPR) — is being developed as a single-dose treatment for hereditary angioedema”

Methods: 80 patients (16 yrs and older) underwent randomization; 52 were assigned to receive lonvo-z and 28 to receive placebo.

Key findings:

  • Between weeks 5-28, there were 62% of the lonvo-z group that had no attacks compared to 11% of the placebo group
  • Safety: “The most common adverse effect (occurring in >10% of the patients in the lonvo-z group) included infusion-related reaction, headache, fatigue, back pain, and upper respiratory tract infection. No serious or grade 3 or higher adverse events were reported in the lonvo-z group”

Discussion points:

  • “The edit to the gene KLKB1 is intended to be permanent after treatment with lonvo-z.”
  • Safety: “Consideration must therefore be given to the long-term safety of plasma prekallikrein knockdown. Reports in the literature of a rare congenital plasma kallikrein deficiency (Fletcher factor deficiency) suggest that such persons are healthy and have prolonged activated partial-thromboplastin time without an associated bleeding risk19…The most prevalent cardiovascular condition reported in persons with congenital plasma kallikrein deficiency is hypertension,20,22 which has not been reported as an adverse event in patients treated with lonvo-z to date.”
  • “Another important consideration is the potential risk of off-target editing…Across all clinical trials conducted with lonvo-z to date, no evidence of adverse effects attributable to off-target editing has been observed.”

My take: This is a remarkable achievement; a single CRISPR infusion may cure individuals with Hereditary Angioedema. Long-term data is needed to more fully understand the safety profile. While this infusion is likely to be quite costly, the currently available treatments are also very expensive and without a defined end-point.

Related blog posts:

Gene Therapy for Alpha-One Antitrypsin Deficiency

An excerpt from NY Times:

Researchers have corrected a disease-causing gene mutation with a single infusion carrying a treatment that precisely targeted the errant gene.This was the first time a mutated gene has been restored to normal….

The study involved patients who have alpha-1 antitrypsin deficiency, or AATD, a genetic disease that affects an estimated 100,000 Americans…

When the nanoparticles reached the liver, the lipid layer peeled off, releasing the editor — a disabled CRISPR molecule that acted like a GPS for the genome and an enzyme to fix the mutation. The CRISPR molecule crawled along the patient’s DNA until it found the one incorrect letter that needed to be repaired among the three billion DNA letters in the genome. Then the editing enzyme replaced that letter with the correct one… Those who got the highest dose made enough normal alpha-1 antitrypsin to be in a range where no more damage should occur. 

My take: This is exciting news, though, long-term data is needed to determine if this will be a durable cure. Cost/availability will be an important consideration if effective.

Related blog posts: